Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Moretta
Allessandro Moretta, Genes IT
| Patent application number | Description | Published |
|---|---|---|
| 20080274468 | NOVEL MEANS FOR THE DIAGNOSIS AND THERAPY OF CTCL - The invention relates to a novel molecule, termed SC5 by the inventors, to a novel allelic form of p140, and to the biological applications of SC5 and p140 molecules, notably in the diagnosis and therapy of CTCL. | 11-06-2008 |
Allessandro Moretta, Genova IT
| Patent application number | Description | Published |
|---|---|---|
| 20110151472 | NOVEL MEANS FOR THE DIAGNOSIS AND THERAPY OF CTCL - The invention relates to a novel molecule, termed SC5 by the inventors, to a novel allelic form of p140, and to the biological applications of SC5 and p140 molecules, notably in the diagnosis and therapy of CTCL. | 06-23-2011 |
Lorenzo Moretta, Genova IT
| Patent application number | Description | Published |
|---|---|---|
| 20080219980 | Bi-Specific Complexes for Targeting Cells Involved in Allergic-Type Reactions, Compositions and Uses Thereof - Disclosed are bi-specific complexes aimed at inhibiting mast cells, eosinophils and/or basophils, and thus, at inhibiting allergy-type reactions. In particular, said complexes are best exemplified by bi-specific antibodies, which bind to two targets present in the same cell. One target is the inhibitory receptor IRp60. The second target is a cell-specific activator, e.g. IgE, cKIT, FcεRI, IL5R or CCR3. Binding of the bi-specific antibody to its targets results in the induction of an inhibitory pathway, through the inhibition of the signaling from the activator. Compositions and uses of the bi-specific complexes are also described. | 09-11-2008 |
| 20100285531 | Therapeutic and Diagnostic Methods and Compositions Targeting 4Ig-B7-H3 and its Counterpart NK Cell Receptor - The present invention relates to the identification of 4Ig-B7-H3 protein as a tumor associated molecule that imparts protection from NK cell-mediated lysis via a 4Ig-B7-H3 receptor on NK cells. The invention provides compounds that interfere with interactions between the 4Ig-B7-H3 protein and its receptor that can be used to potentiate NK cell cytotoxicity. Also provided are compounds that bind 4Ig-B7-H3-expressing cells so as to inhibit or eliminate them. The compounds are particularly useful in the treatment of tumors, inflammatory conditions, infections and transplantation. Also provided are methods for diagnosing disease by detecting a 4Ig-B7-H3 protein. | 11-11-2010 |